Alembic Pharmaceuticals Q2 FY27 Earnings Call: FY27 Guidance Raised to 20-25%, US Generics Jump 72% (APLLTD)

Alembic Pharmaceuticals Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Beat: Revenue, Margins and Profitability All Accelerate

• Consolidated revenue of Rs.2,603 Cr, up 36% YoY — driven by strong performance across all businesses; H1 FY 2026-2027 revenue grew 31% YoY to Rs.4,753 Cr.
• EBITDA grew 78% YoY with margin up ~520 bps to 22.2% — vs 17% in Q2 FY 2025-2026; PBT grew 95% YoY and PAT grew 81% YoY to Rs.335 Cr. Management attributed expansion to operating leverage, new launches and disciplined R&D growth while absorbing planned US branded investment.
• Gross margin expanded 70 bps YoY to 73.7% — within the guided 70-75% range for FY 2026-2027, aided by favorable product mix despite higher solvent costs and geopolitical headwinds.
• Effective tax rate rose to ~24% — vs 18% in Q2 FY 2025-2026; the company moved to a normal 25% tax rate in India effective FY 2026-2027, while cash tax continues at ~18.75% given available MAT credit.
• R&D spend at 8% of revenue in Q2 FY 2026-2027 — focused on complex generics, regulatory filings and the differentiated products pipeline.
• Net debt of Rs.1,236 Cr — less than 1x full-year FY 2026-2027 EBITDA; working capital is elevated on longer collection cycles for new US launches, expected to unwind progressively from Q3 FY 2026-2027 onward.
• Capex of ~Rs.250 Cr in H1 FY 2026-2027 — the major capex cycle is complete; focus shifts to debottlenecking and incremental line additions, which management expects to improve asset turns and returns.

US Exceptional on Exclusivity; India Recovering; API Volume-Led

• US generics grew 72% YoY in Q2 FY 2026-2027, crossing $100 million — the underlying base business (ex-new launches) grew 23%; CFO G. Krishnan noted the core US business (ex-Bosutinib) also grew mid-20s% in Q1 FY 2026-2027, reinforcing that growth is volume-driven.
• Bosutinib exclusivity holds till end of November 2026 — sales ran in line with expectations; the post-exclusivity market shape is uncertain ("we'll see what happens after that").
• India business grew 14% YoY — human health returned to double-digit growth at 11%, with the specialty portfolio growing ~200 bps ahead of the Indian pharmaceutical market; animal health grew 23% in Q2 FY 2026-2027.
• Ex-US markets grew 12% YoY — while the API business delivered volume-led growth of 39% YoY, including certain CMO deliveries to key customers during the quarter.
• US branded (Alembic Therapeutics) contributed close to 3% of total US revenue — with 4 branded products all contributing; prescription trends, formulary access and physician response progressing in line with plan.

30+ Launch Cadence and a $5 Bn Complex Generics Basket

• 30+ US launches expected over the next 18 months (from Q2 FY 2026-2027) — about a quarter (~25%) comprising FTF or shared day-one opportunities, cited as the basis for continued FTF replenishment as the current FTF portfolio normalizes.
• Expanded DiffGen Pharmaceuticals collaboration gives access to 20+ products — across transdermal patches, complex injectables, ophthalmics and other specialized dosage forms, addressing an aggregate US reference market of ~$5 billion, plus access to US manufacturing capacity that can be reserved for Alembic; contributions expected to begin from FY28.
• DiffGen deal is a licensing arrangement on a profit-share basis — structured as a basket approach rather than one-off deals; DiffGen will manufacture most products, with Alembic manufacturing some. Rationale: DiffGen has no front-end presence (which Alembic provides) and brings dosage-form capabilities Alembic lacks, plus several FTFs and day-one launches.
• Management declined product-wise forecasts for upcoming US patent expiries — Kenil Mehta cited Prolia, Tovias and Aptravy/Uptravi expiring "in the next few quarters"; Pranav Amin noted Uptravi carries shared exclusivity on some strengths and sole exclusivity on others, citing "too many variables" and leaving forecasts to analysts. He also declined to project the margin impact of FTF launches.
• Ophthalmics is a very strong franchise — management believes Alembic holds the #1 or #2 position in most products it is present in (share data to be shared offline); a line shutdown for capacity expansion caused a minor blip in Q4 FY 2025-2026 and Q1 FY 2026-2027. Derma delivers good share and high EBITDA but is more competitive than ophthalmics.
• Contract manufacturing is pursued in select facilities — focused on sterile and oncology, with contracts in place, structured as pure contract manufacturing (not cost-plus markup or profit-sharing); share of injectable sales for Q2 FY 2026-2027 not quantified.

Chronic Leading the Recovery; Acute Still Lagging IPM

• Commercial interventions are delivering results — CFO G. Krishnan said sharper territory-level execution, improved field force productivity (focused on chronic portfolios) and wider geographical spread drove all chronic divisions to grow well YoY with better-than-IPM growth in Q2 FY 2026-2027.
• Acute still lags but management is "quite confident" it reaches IPM level over the next couple of quarters — with the overall India business at IPM or higher in Q3-Q4 FY 2026-2027; metro coverage remains weak and needs improvement.
• Q2 FY 2026-2027 India growth was volume-led — exact breakup not disclosed, but directionally almost 50-50 between price and volume plus new launches.
• Margin improvement path runs through growth, not field force expansion — MD Pranav Amin said the first priority is reaching market-rate (IPM) growth in Q3-Q4 FY 2026-2027; with no field force expansion, steady growth should lead to higher PCPM and gradual margin improvement thereafter.
• Animal health supports the India trajectory — analyst Rahul Jeewani (IIFL) noted the business has been delivering ~20-25% growth (a CAGR of over 20% over the last 5-7 years), which should help sustain double-digit growth for the overall India business; Pranav Amin affirmed. Companion-animal opportunities (including for US/Europe markets) are being evaluated but there is "no firm strategy as yet."

Pivya Ramp Underway; Break-Even Targeted from H1 FY 2027-2028

• Pivya is tracing a J-shaped curve with prescriptions gradually rising — among Nuvessa, NuvaTest and Pivya, the two established products are ramping faster; management expects Pivya to contribute meaningfully through H2 FY 2026-2027 into the start of FY 2027-2028. Management does not disclose product-wise prescription counts.
• Break-even expected by end of FY 2026-2027, with break-even in H1 FY 2027-2028 — the 150-200 bps drag from the US branded business is on a full-year basis for FY 2026-2027, with no drag in FY28.
• Field force build-out on track: ~30-35 reps currently vs a goal of 40-45 — as of Q2 FY 2026-2027; channel access is established, with coverage secured from insurance companies as well as Medicaid (not reliant on cash/direct pay) — "all on track."
• Long-term branded contribution target exists internally but no external guidance yet — Pranav Amin said guidance is expected by end of FY 2026-2027, once H2 FY 2026-2027 provides more confidence on the ramp-up.
• Q2 FY 2026-2027 gross margin of ~74% cascaded to ~21% EBITDA margin — vs pre-exclusivity gross margins of 70-72% translating to ~16% EBITDA margins; CFO G. Krishnan stated gross margin will be in the normal range of 70-75% (period unspecified), with any upside from select products taken as it comes. Despite the improving India (IPM) mix, management expects the margin to remain within that range rather than bump higher.
• Two levers toward ~20% EBITDA — operating leverage from existing facilities (utilization already ramped up with good visibility of continuing) and elimination of the US branded drag from FY 2027-2028. Asked whether ~20% EBITDA is envisaged for FY28-FY29, Pranav Amin said the company "would like to go towards those kind of margins" — aspirational rather than a committed target.
• Cost headwinds absorbed — employee costs rose on increments (India field force headcount held constant) plus US branded field force expansion, in line with the FY 2026-2027 budget; other expenses rose on promotions, US branded expansion and higher freight/logistics costs (visible since the March 2026 quarter, dependent on where crude oil settles). Crude-driven raw material inflation was balanced out by currency depreciation in Q2 FY 2026-2027; no steady-state gross margin excluding crude impact was quantified.

FY27 Guidance Raised; FY28 US Growth Moderates to 10-12%

• FY27 consolidated revenue growth guidance raised to ~20-25% — up from the mid-teens indicated last quarter (Q1 FY27), incorporating the expected normalization of exclusivity-led sales.
• FY27 US business expected to grow up to 40% YoY — with API expected to deliver at least high-teens growth; India branded expected to grow close to market/double digits and ex-US at mid-teens (India and ex-US outlook unchanged).
• FY28 US growth guided at about 10-12% — MD Pranav Amin confirmed FY27 will be a high-base growth year, with the FY28 guidance contingent on the upcoming launches panning out well.
• FY 2026-2027 full-year EBITDA margin guided at high-teens — with the margin profile expected to hold for the rest of the year; high-teens gross margins achieved in H1 FY 2026-2027 are expected to continue in H2 FY 2026-2027.
• H2 FY 2026-2027 priorities — sustain execution, convert pipeline into new launches, build momentum in India branded and US branded businesses, and translate growth into durable earnings and returns.